NASDAQ:CBPO - China Biologic Products Stock Price, Forecast & News

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its quarterly earnings results on Wednesday, November, 13th. The biopharmaceutical company reported $1.40 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.88 by $0.52. The biopharmaceutical company had revenue of $136.10 million for the quarter. China Biologic Products had a return on equity of 9.79% and a net margin of 31.22%. China Biologic Products's quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.96 EPS. View China Biologic Products' Earnings History.

China Biologic Products is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for China Biologic Products.

2 brokers have issued twelve-month price targets for China Biologic Products' stock. Their forecasts range from $62.00 to $88.00. On average, they expect China Biologic Products' stock price to reach $75.00 in the next twelve months. This suggests that the stock has a possible downside of 35.6%. View Analyst Price Targets for China Biologic Products.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.

News stories about CBPO stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. China Biologic Products earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for China Biologic Products.

China Biologic Products saw a drop in short interest during the month of December. As of December 13th, there was short interest totalling 536,800 shares, a drop of 11.1% from the November 28th total of 603,900 shares. Based on an average daily volume of 99,500 shares, the days-to-cover ratio is currently 5.4 days. Approximately 3.2% of the company's stock are sold short. View China Biologic Products' Current Options Chain.

Some companies that are related to China Biologic Products include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BioNTech (BNTX), BIO-TECHNE (TECH), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), Gilead Sciences (GILD), Biogen (BIIB), Sarepta Therapeutics (SRPT), Amgen (AMGN), The Carlyle Group (CG), GSI Technology (GSIT), Netflix (NFLX), AbbVie (ABBV) and Alibaba Group (BABA).

China Biologic Products' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.00%). View Institutional Ownership Trends for China Biologic Products.

CBPO stock was acquired by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. View Insider Buying and Selling for China Biologic Products.

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBPO stock can currently be purchased for approximately $116.50.

China Biologic Products has a market capitalization of $4.59 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe.View Additional Information About China Biologic Products.

The official website for China Biologic Products is http://www.chinabiologic.com/.

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]